此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

上皮性卵巢癌 (MATAO) 中芳香化酶抑制剂的维持治疗 (MATAO)

2026年11月16日 更新者:Swiss GO Trial Group

使用芳香化酶抑制剂治疗上皮性卵巢癌:随机双盲安慰剂对照多中心 III 期试验 (ENGOT-ov54/Swiss-GO-2/MATAO),包括 LOGOS(低级别卵巢癌子研究)。

The purpose of this study is to evaluate the efficacy of addition of letrozole to the standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor (ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of the participants will receive to the standard maintenance treatment, letrozole, whilst the other half receives placebo.

The study's primary hypothesis is that the treatment with letrozole increases progression free survival in comparison to the maintenance standard treatment (superiority trial).

研究概览

详细说明

Femara (letrozole) is an extensively investigated, marketed aromatase inhibitor (AI) widely used as treatment in the maintenance phase of estrogen-receptor (ER) positive breast cancer, as it inhibit the synthesis of estrogens. Estrogen is a well known driver of cancer growth in ER-positive tumors and a high percentage of the epithelial ovarian cancers express ER as well. Of which low grade ovarian cancers demonstrates the highest level of expression, supporting our strategy of a sub-group analysis (LOGOS). Therefore, letrozole in this study be investigated prospectively and evaluated as maintenance therapy after standard surgical and chemotherapy treatment in comparison to placebo (which is the current standard maintenance treatment) in subjects with primary, ER-positive low or high grade serous or endometrioid epithelial ovarian cancer (including fallopian tube and primary peritoneal cancer) of FIGO Stage II-IV, whose cancer has not progressed by the end of the platinum-based chemotherapy.

The objectives are to evaluate the letrozole maintenance treatment compared to placebo in terms of

  • progression-free survival (PFS; primary endpoint)
  • overall survival (OS)
  • quality-adjusted progression free survival (QAPFS)
  • time to first subsequent treatment (TFST)
  • quality-adjusted time without symptoms of toxicity (Q-TWiST)
  • health related quality of life (QoL) assessed by EQ-5D-5L, FACT-ES and FACT-O questionnaires

Methods: 540 for this study eligible subjects are 1:1 allocated in this randomized, controlled, double-blinded, multi-centre study to either the test (letrozole) or control (placebo) group. The maximum maintenance treatment duration is 5 years or until symptoms of toxicity or progression of underlying disease.

Health and health-related quality of life will continuously be assessed at study entry and during routine recalls which are scheduled every 12 weeks for the first 2 years, followed by every 24 weeks for the next 3 years. Procedures performed to assess the participants' health are the same as are performed during the regular routine ovarian cancer follow-up visits: blood tests, physical as well as gynaecological examinations and may include imaging. In addition, the participants are asked to complete during the study quality of life (QoL) specific questionnaires and wear an activity tracker for one week just before the scheduled visits. These assessments will be used for the evaluation of letrozole's efficacy and burden in comparison to the standard maintenance treatment. Survival follow-up data after the mainentance treatment duration of 5 years (study end) are obtained for up to another 7 years.

研究类型

介入性

注册 (估计的)

540

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Graz、奥地利、8036
        • Medizinische Universität Graz
      • Graz、奥地利、8020
        • Krankenhaus der Barmherzigen Brüder Graz
      • Innsbruck、奥地利、6020
        • Medizinische Universität Innsbruck
      • Leoben、奥地利、8700
        • Landeskrankenhaus Hochsteiermark Leoben
      • Linz、奥地利、4010
        • Ordensklinikum Linz Barmherzige Schwestern
      • Salzburg、奥地利、5020
        • Universitätsklinikum Salzburg
      • Vienna、奥地利、1090
        • Medizinische Universität Wien
      • Vienna、奥地利、1130
        • Klinik Hietzing Wien
      • Berlin、德国、13353
        • Charité - Universitätsmedizin Berlin Campus Virchow Klinikum
      • Cologne、德国、50935
        • St. Elisabeth-Krankenhaus
      • Deggendorf、德国、94469
        • Donauisar Klinikum
      • Dresden、德国、01307
        • Universitätsklinikum Carl Gustav Carus Dresden
      • Düsseldorf、德国、40225
        • Universitätsklinikum Düsseldorf
      • Düsseldorf、德国、40217
        • Evangelisches Krankenhaus Düsseldorf
      • Essen、德国、45136
        • Evangelische Kliniken Essen Mitte GmbH
      • Esslingen am Neckar、德国、73730
        • Klinikum Esslingen
      • Freiburg im Breisgau、德国、79106
        • University Hospital Freiburg
      • Hamburg、德国、20251
        • The University Medical Center Hamburg-Eppendorf
      • Hamburg、德国、20259
        • Agaplesion Diakonieklinikum Hamburg
      • Hildesheim、德国、31134
        • Gynäkologisch-Onkologische Gemeinschaftspraxis Dres. med. C.Uleer/J.Y.Pourfard
      • Konstanz、德国、78464
        • Klinikum Konstanz
      • Mainz、德国、55131
        • Universitätsmedizin Mainz
      • Mannheim、德国、68167
        • Universitätsklinikum Mannheim
      • Münster、德国、48149
        • University Hospital Münster
      • Ravensburg、德国、88212
        • Studienzentrum Onkologie Ravensburg
      • Rosenheim、德国、83022
        • SL Klinikum Rosenheim
      • Schweinfurt、德国、97422
        • Leopoldina Krankenhaus der Stadt Schweinfurt
      • Ulm、德国、89075
        • Universitätsklinik Ulm
      • Wiesbaden、德国、65199
        • Helios Dr. Horst Schmidt Kliniken Wiesbaden
      • Wolfsburg、德国、38440
        • AMO Wolfsburg / AMO MVZ GmbH
      • Wuppertal、德国、42117
        • Helios Universitätsklinikum Wuppertal
      • Baden、瑞士、5404
        • Kantonsspital Baden AG
      • Basel、瑞士、4002
        • Basel Claraspital AG
      • Bern、瑞士、3010
        • Universitätsklinik für Medizinische Onkologie, Inselspital
      • Bern、瑞士、3012
        • Praxis im Frauenzentrum Lindenhofspital
      • Chur、瑞士、7000
        • Kantonspital Graubünden (KSGR),
      • Frauenfeld、瑞士、8501
        • Kantonsspital Frauenfeld
      • Geneva、瑞士、1205
        • Hôpitaux Universitaires de Genève
      • Grabs、瑞士、9472
        • Frauenklinik Spital Grabs
      • Lausanne、瑞士、1011
        • Universitätsspital Waadt/ CHUV
      • Liestal、瑞士、4410
        • Kantonsspital Baselland
      • Lucerne、瑞士、6000
        • Luzerner Kantonsspital
      • Lucerne、瑞士、6006
        • Tumorzentrum Hirslanden Klinik St. Anna
      • Münsterlingen、瑞士、8596
        • Kantonsspital Münsterlingen
      • Sankt Gallen、瑞士、9007
        • Kantonsspital St. Gallen
      • Winterthur、瑞士、8401
        • Kantonsspital Winterthur
      • Zurich、瑞士、8063
        • Stadtspital Triemli
      • Zurich、瑞士、8032
        • Klinik für Onkologie und Hämatologie Hirslanden Zürich AG
      • Zurich、瑞士、8091
        • Unispital Zürich
    • Canton Ticino
      • Bellinzona、Canton Ticino、瑞士、6500
        • Oncology Institute of Southern Switzerland (IOSI)-Ente Ospedaliero Cantonale (EOC)
    • Canton of Aargau
      • Aarau、Canton of Aargau、瑞士、5001
        • Kantonsspital Aarau AG
    • Canton of Basel-City
      • Basel、Canton of Basel-City、瑞士、4031
        • Universitätsspital Basel
    • Valais
      • Sion、Valais、瑞士
        • Centre Hospitalier du Valais Romand

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Patients must be ≥ 18 years of age
  • Willing and able to attend the visits and to understand all study-related procedures.
  • Primary, newly diagnosed FIGO Stage II to IV and histologically confirmed low or high grade serous or endometrioid epithelial ovarian/fallopian tube/peritoneal cancer
  • (Interval-) debulking performed ECOG-Performance Status 0-2
  • Signed informed consents (ICF-1; ICF-2)
  • Paraffin-embedded tissue or paraffin-embedded cell block (from ascites) available
  • Positivity (≥ 1%) for ER expression (only determined by Histopathology Core Facility of MATAO trial)
  • At least 4 cycles of platinum-based chemotherapy (neoadjuvant allowed)
  • Negative serum pregnancy test in women of childbearing potential who will get/have gotten a surgical resection or radiation sterilization, prior to the intervention in the therapeutical maintenance setting.

Exclusion Criteria:

  • Progressive disease at the end of adjuvant treatment as defined in chapter 9.2.1 of protocol
  • Women of childbearing potential (not having undergone a surgical or radiation sterilization and not getting a surgical resection, prior to the intervention in the therapeutical maintenance setting)
  • Pregnant or lactating women
  • Any other malignancy within the last 5 years which has impact on the prognosis of the patient
  • < 4 cycles of chemotherapy in total
  • Contraindications to endocrine therapy
  • Inability or unwillingness to swallow tablets
  • Patients with a known intolerance to galactose, lactase deficiency and glucose-galactose malabsorption

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Letrozole (aromatase inhibitor)

Letrozole, 2.5 mg Femara tablet, administered once daily for 5 years or until symptoms of toxicity or progression of underlying disease

Aromatase inhibitor

其他名称:
  • 费马拉
安慰剂比较:Placebo

Placebo tablet of Femara (without aromatase inhibitor), 0 mg Femara tablet, administered once daily for 5 years or progression of underlying disease

Placebo tablet of Femara

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression-free survival (PFS) for each study group
大体时间:Up to approximately 12 years

PFS defined as the time from the date of first IMP administration until the date of progression (recurrence) or death by any cause in the absence of progression.

Assessment of progression (recurrence) is generally indicated by SYMPTOMS and will be assessed by the investigator most commonly on the basis of CT scans of the pelvis, abdomen and thorax, according to RECIST v1.1 criteria recommended and mostly presented by an elevated CA-125 level. Elevated CA-125 levels alone shouldn't be considered as progression. Progression assessment according to local standard of care, however, is similarly acceptable.

Up to approximately 12 years

次要结果测量

结果测量
措施说明
大体时间
Overall survival (OS) for each study group
大体时间:Up to approximately 12 years

OS defined for each patient as the time from the date of first IMP administration until the date of death from any cause. Patients not having an event at the time of analysis will be censored at the date they were last known to be alive.

Up to approximately 12 years
Quality-adjusted progression free survival (QAPFS) for each study group
大体时间:Up to approximately 12 years

QAPFS defined as the time from the date of first IMP administration until the date of progression (recurrence) or death by any cause in the absence of progression under consideration of the quality of life during this period. QAPFS incorporates progression-free survival (quantity) and quality of life during this period into a measure of net clinical benefit:

QAPFS = PFS (years or months) x QoL (utility value).

Utility values derived from the EQ-5D-L5 questionnaire will be used.

Up to approximately 12 years
Time to first subsequent treatment (TFST) for each study group
大体时间:Up to approximately 12 years

TFST defined for each patient as the time from the date of first IMP administration until the date the patient started the next (second-line) subsequent anticancer treatment. Patients not receiving a subsequent anticancer treatment at the time of analysis will be censored at the date they were last known to be alive.

Up to approximately 12 years
Quality-adjusted time without symptoms of toxicity (Q-TWiST) for each study group
大体时间:Up to approximately 12 years

Q-TWiST defined as the Quality adjusted Time Without appearance of any Symptoms of Toxicity related to either the progression of the cancer or side effects of the trial medication from the date of first IMP administration until dead.

The Q-TWiST analysis considers the following three health states:

  • (1) the period experiencing toxicity (TOX)
  • (2) the period before progression without experiencing toxicity (TWiST)
  • (3) the period after relapse (REL)

These periods are assigned preference utilities (u), which will be derived using the generic EQ-5D-5L questionnaire.

The Q-TWiST will be calculated as the weighted sum of the time spent in each health state:

Q-TWiST = uTox*TOX + TWiST + uRel*REL where u denotes the assigned utility for each respective health state.

Up to approximately 12 years
Health related quality of life (QoL) assessed byFunctional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) questionnaire for each study group
大体时间:Up to approximately 5.25 years

Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) is included into the study to more specifically assess the side effects from the IMPs on quality of life. The minimum value is 0, the maximum value for the specific 19 item Endocrine Symptom Subscale (ESS-19) is 76. The higher the score, the better the QOL

Up to approximately 5.25 years
Health related quality of life (QoL) assessed by Functional Assessment of Cancer Therapy - Ovarian (FACT-O) questionnaire for each study group
大体时间:Up to approximately 5.25 years

In the context of this study the specific ovarian cancer symptom-oriented questionnaire Functional Assessment of Cancer Therapy - Ovarian (FACT-O) is included to assess the progression/recurrence of ovarian cancer on Quality of Life. The minimum value is 0, the maximum value including the specific Ovarian Cancer Subscale (OCS) is 152. The higher the score, the better the QOL

Up to approximately 5.25 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2020年11月5日

初级完成 (估计的)

2028年2月1日

研究完成 (估计的)

2033年2月1日

研究注册日期

首次提交

2019年9月30日

首先提交符合 QC 标准的

2019年9月30日

首次发布 (实际的)

2019年10月2日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • ENGOT-ov54/Swiss-GO-2/MATAO
  • 2019-002264-27 (EudraCT编号)
  • ENGOT-ov54 (其他标识符:European Network for Gynaecological Oncological Trial Groups)
  • Swiss-GO-2 (其他标识符:Swiss Network for Gynaecological Oncological Studies)
  • 2024-511219-78-00 (克蒂斯)
  • AGO-OVAR 26 (其他标识符:AGO Deutschland)
  • AGO 65 (其他标识符:AGO Austria)

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅